A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
Latest Information Update: 10 Jun 2024
At a glance
- Drugs RGH-706 (Primary)
- Indications Prader-Willi syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Gedeon Richter
Most Recent Events
- 30 May 2024 Status changed from active, no longer recruiting to completed.
- 22 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 04 Sep 2022 Status changed from not yet recruiting to recruiting.